Vilazodone and CYP3A4 inhibition

Trial Profile

Vilazodone and CYP3A4 inhibition

Phase of Trial: Phase II

Latest Information Update: 03 Dec 2015

At a glance

  • Drugs Vilazodone (Primary) ; Ketoconazole
  • Indications Generalised anxiety disorder; Major depressive disorder; Sexual function disorders; Social phobia
  • Focus Pharmacodynamics; Pharmacokinetics
  • Sponsors Forest Laboratories; PGxHealth
  • Most Recent Events

    • 03 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top